BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Vrije Universiteit Amsterdam//NONSGML v1.0//EN
NAME:PhD defence N.E. Wijnen
METHOD:PUBLISH
BEGIN:VEVENT
DTSTART:20260615T154500
DTEND:20260615T171500
DTSTAMP:20260615T154500
UID:2026/phd-defence-n-e-wijnen@8F96275E-9F55-4B3F-A143-836282E12573
CREATED:20260530T121204
LOCATION:(1st floor) Auditorium, Main building De Boelelaan 1105 1081 HV Amsterdam
SUMMARY:PhD defence N.E. Wijnen
X-ALT-DESC;FMTTYPE=text/html: <html> <body> <p>Cure and Care: Delicate
  Balance in Global Pediatric Acute Myeloid Leukemia</p> <p>“The mos
 t important factor determining whether a child diagnosed with cancer 
 will survive is not the biology of the disease, but the country in wh
 ich the child is treated.” This reflects the profound global dispar
 ities in childhood cancer outcomes. While survival exceeds 80% in hig
 h-income countries, it often remains below 30% in low- and middle-inc
 ome countries, where most children with cancer live. This thesis focu
 ses on pediatric acute myeloid leukemia (AML), a malignant disorder o
 f the bone marrow with particularly poor outcomes in resource limited
  settings. Unfortunately, there is no simple cure for AML. Treating A
 ML requires a careful balance between anti-cancer treatment and suppo
 rtive care: delivering sufficiently intensive treatment to achieve cu
 re, while preventing treatment-related morbidity and mortality. This 
 balance is highly context-dependent and shapes global survival differ
 ences. The studies presented provide a global perspective on pediatri
 c AML, identify new treatment strategies, and aim to enhance supporti
 ve care. By combining global perspectives with clinical and translati
 onal research, this thesis aims to contribute to more equitable, cont
 ext-appropriate, and ultimately curative strategies for children with
  AML worldwide.</p><p>More information on the <a href="https://hdl.ha
 ndle.net/1871.1/acde3558-736a-4d50-be35-5575c03e7116" data-new-window
 ="true" target="_blank" rel="noopener noreferrer">thesis</a></p> </bo
 dy> </html>
DESCRIPTION: “The most important factor determining whether a child 
 diagnosed with cancer will survive is not the biology of the disease,
  but the country in which the child is treated.” This reflects the 
 profound global disparities in childhood cancer outcomes. While survi
 val exceeds 80% in high-income countries, it often remains below 30% 
 in low- and middle-income countries, where most children with cancer 
 live. This thesis focuses on pediatric acute myeloid leukemia (AML), 
 a malignant disorder of the bone marrow with particularly poor outcom
 es in resource limited settings. Unfortunately, there is no simple cu
 re for AML. Treating AML requires a careful balance between anti-canc
 er treatment and supportive care: delivering sufficiently intensive t
 reatment to achieve cure, while preventing treatment-related morbidit
 y and mortality. This balance is highly context-dependent and shapes 
 global survival differences. The studies presented provide a global p
 erspective on pediatric AML, identify new treatment strategies, and a
 im to enhance supportive care. By combining global perspectives with 
 clinical and translational research, this thesis aims to contribute t
 o more equitable, context-appropriate, and ultimately curative strate
 gies for children with AML worldwide. More information on the <a href
 ="https://hdl.handle.net/1871.1/acde3558-736a-4d50-be35-5575c03e7116"
  data-new-window="true" target="_blank" rel="noopener noreferrer">the
 sis</a> Cure and Care: Delicate Balance in Global Pediatric Acute Mye
 loid Leukemia
END:VEVENT
END:VCALENDAR
